Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
0.7000
+0.0422 (6.42%)
At close: May 19, 2025, 4:00 PM
0.6993
-0.0007 (-0.10%)
After-hours: May 19, 2025, 7:49 PM EDT
Adial Pharmaceuticals Employees
Adial Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,789,938
Market Cap
4.60M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ADIL News
- 4 days ago - Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 days ago - Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - GlobeNewsWire
- 17 days ago - Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds - GlobeNewsWire
- 18 days ago - Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04 - GlobeNewsWire
- 3 months ago - Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies - GlobeNewsWire
- 3 months ago - Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - GlobeNewsWire